Protagonist Therapeutics (PTGX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$2.14 (-4.95%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Protagonist Therapeutics (PTGX)
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Key Insights

Critical company metrics and information
  • Share Price

    $41.60
  • Market Cap

    $2.48 Billion
  • Total Outstanding Shares

    59.60 Million Shares
  • Total Employees

    126
  • Dividend

    No dividend
  • IPO Date

    August 11, 2016
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.protagonist-inc.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-352.05 Million
Net Cash Flow From Operating Activities$230.29 Million
Net Cash Flow, Continuing$-99.41 Million
Net Cash Flow From Financing Activities, Continuing$22.35 Million
Net Cash Flow From Financing Activities$22.35 Million
Net Cash Flow From Investing Activities$-352.05 Million
Net Cash Flow$-99.41 Million
Net Cash Flow From Operating Activities, Continuing$230.29 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income Tax Expense/Benefit$2.23 Million
Preferred Stock Dividends And Other Adjustments$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Income/Loss$149.11 Million
Diluted Earnings Per Share$2.74
Net Income/Loss Available To Common Stockholders, Basic$170.85 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations Before Tax$173.08 Million
Operating Expenses$174.68 Million
Basic Average Shares$62.53 Million
Income/Loss From Continuing Operations After Tax$170.85 Million
Basic Earnings Per Share$2.86
Diluted Average Shares$65.83 Million
Other Operating Expenses$42.56 Million
Net Income/Loss Attributable To Parent$170.85 Million
Net Income/Loss$170.85 Million
Revenues$323.80 Million
Research and Development$132.12 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Accounts Payable$3.05 Million
Other Non-current Assets$124.62 Million
Current Assets$476.77 Million
Equity$531.91 Million
Noncurrent Liabilities$27.36 Million
Other Current Liabilities$41.53 Million
Equity Attributable To Noncontrolling Interest$0.00
Current Liabilities$44.58 Million
Equity Attributable To Parent$531.91 Million
Fixed Assets$2.47 Million
Liabilities And Equity$603.86 Million
Noncurrent Assets$127.09 Million
Liabilities$71.94 Million
Assets$603.86 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.